EssilorLuxottica and MidEuropa have announced an agreement for EssilorLuxottica to acquire Optegra, a rapidly growing and highly integrated ophthalmology platform that operates in five major European markets: the UK, the Czech Republic, Poland, Slovakia, and the Netherlands.
This acquisition marks a significant step in EssilorLuxottica’s med-tech strategy, expanding the company’s offerings beyond just frames and lenses. The group’s portfolio now includes AI-driven technologies, wearables, medical instruments, and science-backed eyecare solutions, all aimed at improving the lives of millions.
Optegra operates a robust network of over 70 eye hospitals and diagnostic facilities across Europe, offering essential ophthalmic treatments and elective vision correction procedures. These services are enhanced by AI support in both the pre- and post-operative stages. Key treatments include cataract surgery, treatments for age-related macular degeneration and glaucoma, refractive lens replacement, and laser eye surgery. Optegra serves both publicly reimbursed and privately insured patients.
Since its founding in 2007, Optegra has built a strong reputation for clinical leadership, with highly ranked surgeons and medical teams delivering quality care and exceptional outcomes. This makes Optegra a perfect fit for EssilorLuxottica’s growing med-tech portfolio.
The deal is expected to close in late 2025, pending regulatory approvals and other standard conditions.
Related topics:
